Work

Clinical and Molecular Prognostic Factors and Targeted Therapy Outcomes in Colorectal Cancer with Bone and Brain Metastases: A Multicenter Retrospective Turkish Oncology Group Study

Year: 2026
Type: article
Study design: Observational Study
Abstract: Bone and brain metastases are rare in colorectal cancer, and prior studies have treated metastasis as a fixed baseline characteristic. We conducted a multicenter retrospective study of patients with colorectal cancer and bone and/or brain metastases at Turkish Oncology Group centers (May 2011 to September 2025). In multivariable Cox models, the opposite rare-site metastasis and post-metastasis targeted therapy were modeled as time-dependent covariates. Among 188 patients, 139 (73.9%) had bone-first, 33 (17.6%) brain-first, and 16 (8.5%) synchronous disease. Median overall survival was 13.6 months (95% CI 11.6 to 16.4), with no difference by phenotype (p = 0.705). Opposite-site involvement was associated with higher mortality in the bone-metastasis (aHR 2.149, p = 0.006) and brain-metastasis (aHR 2.076, p = 0.018) cohorts, reflecting brain metastasis developing during follow-up in the former and bone metastasis present at diagnosis in the latter. Carcinoembryonic antigen and neutrophil-to-lymphocyte ratio were independently prognostic (both p < 0.01). Anti-EGFR (aHR 0.356, p = 0.001) and anti-VEGF therapy (aHR 0.471, p = 0.005) were associated with lower mortality in patients with bone metastasis but not in those with brain metastasis. Brain metastasis developing in patients with bone metastases carries independent prognostic weight, while targeted-therapy associations in brain metastasis remain inconclusive.
Authors: Kadriye Başkurt(Conceptualization, Data curation, Resources, Writing – original draft, Writing – review & editing), Galip Can Uyar(Formal analysis, Methodology, Software), Enes Yeşilbaş(Data curation, Formal analysis, Project administration), Mahmut Büyükşimşek(Data curation, Investigation, Resources), Elif Sertesen Çamöz(Data curation, Investigation, Resources), Emre Yılmaz(Data curation, Methodology, Resources), İlhan Hacıbekiroğlu(Data curation, Methodology, Resources), Fatma Yalçın Müsri(Data curation, Methodology, Resources), Tuba Uğur Tuzcu(Data curation, Investigation, Resources), Gizem Bakır Kahveci(Data curation, Investigation, Resources), Lamia Şeker Can(Data curation, Methodology, Resources), Hacı Mehmet Türk, Melike Dönmez Tekin(Data curation, Investigation, Resources), Mustafa Şahbazlar(Data curation, Resources, Supervision), Murat Günaltili(Data curation, Resources, Software), Nebi Serkan Demirci(Data curation, Resources, Supervision), Mustafa Ersoy(Data curation, Investigation, Resources), Nargiz Majidova(Data curation, Investigation, Resources), Nilüfer Avcı(Data curation, Investigation, Resources), Sabin Göktaş Aydın(Data curation, Investigation, Resources), Semra Taş(Data curation, Investigation, Resources), Burcu Yapar Taşköylü(Investigation, Resources, Supervision), Sezin Yıldızhan(Data curation, Investigation, Resources), Senem Karabulut(Data curation, Resources, Supervision), Teoman Şakalar(Data curation, Resources, Supervision), Tuğba Akın Telli(Data curation, Resources, Supervision), Hülya Odabaşı Bükün(Data curation, Investigation, Resources), Ahmet Bilgehan Şahin(Data curation, Investigation, Resources), Ömür Berna Çakmak Öksüzoğlu(Project administration, Resources, Supervision), Kadriye Bir Yücel(Formal analysis, Resources, Validation), Osman Sütcüoğlu(Conceptualization, Project administration, Writing – review & editing)
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,654
OpenAlex ID: W7235252335
FWCI:
Cites: 16
Cited by:
Related to: 10